In this edition, tumor mutational burden linked to immunotherapy response; toripalimab regimen extends EFS in stage III NSCLC; phase 3 study designed for increasing trial diversity, and more. Read the full coverage here: Tumor mutational burden may be linked to immunotherapy response in advanced cancers Perioperative toripalimab regimen extends EFS in resectable stage III NSCLC Phase 3 study of lung cancer regimen designed to be a model for increasing trial diversity Smoking cessation before lung cancer diagnosis significantly reduces excess mortality risk Pembrolizumab active in diffuse malignant peritoneal mesothelioma References: Aggarwal C, et al. JAMA Netw Open. 2023;doi:10.1001/jamanetworkopen.2023.11181. Lu S, et al. Abstract 425126. Presented at: ASCO Plenary Series: April 2023 Session; April 20, 2023. Marmarelis ME, et al. JAMA Netw Open. 2023;doi:10.1001/jamanetworkopen.2023.2526. Pragmatica-Lung Study, a streamlined model for future cancer clinical trials, begins enrolling patients (NCI press release). Published April 12, 2023. Accessed April 12, 2023. Wang X, et al. JAMA Netw Open. 2023;doi:10.1001/jamanetworkopen.2023.11966.

Ver todos los episodios